Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We evaluated whether PSVs in BRCA1/2 were associated with risk of overall PCa or high grade (Gleason 8+) PCa using an international sample of 65 BRCA1 and 171 BRCA2 male PSV carriers with PCa, and 3,388 BRCA1 and 2,880 BRCA2 male PSV carriers without PCa.
|
31723001 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Sixteen BRCA1 and 26 BRCA2 carriers were diagnosed with PCa during follow-up.
|
31495749 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
The purpose of this article is to provide a review of principles of genetic testing in prostate cancer and highlight the significance of clinical genetic testing of BRCA1/2 and other genes (CHEK2, HOXB13, PALB2), including Lynch syndrome genes (MLH1, MSH2, MSH6, and PMS2) in men with metastatic prostate cancer.
|
30681994 |
2019 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations.
|
31537406 |
2019 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
In order to substantiate the data for BRCA1 gene loss in PCa and reveal its phenotypical background, BRCA1 gene status was assessed in a large cohort of PCa patients and compared to different molecular factors.
|
30265376 |
2019 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Present study demonstrated that BRCA1 and EZH2 are coregulated in patients' tumors and PCa cell lines, and cooperate in regulation of CSC phenotype and properties.
|
30968962 |
2019 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To better understand the correlation between BRCA1/2 mutations and the immune phenotype in prostate cancer, we characterized the immune infiltrate of eight BRCA2-mutated tumors in comparison with eight BRCA1/2 wild-type patients by T-cell receptor sequencing and immunohistochemistry for CD45, CD4, CD8, FOXP3, and CD163.
|
31549213 |
2019 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Of 3607 men (mean [SD] age at testing, 67 [9.51] years; mean age at diagnosis, 60 [9.05] years) with a personal diagnosis of prostate cancer who were referred for genetic testing, 620 (17.2%) had positive germline variants, of which only 30.7% were variants in BRCA1/2.
|
30730552 |
2019 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
For advanced prostate cancer carrying Breast cancer1/2 <i>(BRCA1/2)</i> or ataxia telengiectasia mutated (<i>ATM</i>) mutations, preclinical studies and clinical trials support the use of PARP-inhibitors, which received breakthrough therapy designation by the FDA.
|
31242618 |
2019 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
IES mean intrusion and avoidance scores were significantly higher in BRCA1/BRCA2 carriers than in controls and were higher in men with increased PCa risk perception.
|
29802810 |
2019 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRCA1 and BRCA2 genes were sequenced (Ion AmpliSeq targeted sequencing) in archived blood DNA specimens in 1240 PCa patients, including 30% AA patients, in three different cohorts: localized early stage (T2) PCa (N = 935); advanced PCa (50% T3-4) (N = 189); and metastatic PCa (N = 116).
|
30542053 |
2019 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRCA2 but not BRCA1 mutations were associated with higher PCa mortality.
|
30900310 |
2019 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Men on active surveillance with inherited mutations in BRCA1/2 and ATM are more likely to harbor aggressive prostate cancer.
|
30309687 |
2019 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In the present study it was demonstrated that PARP1-siRNA could reduce prostate cancer (PCa) cell progression regardless of the BRCA1/2 mutation.
|
29393407 |
2018 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The FDA authorized 23andMe to market the first direct-to-consumer test to check for three BRCA1/2 mutations associated with a higher risk of developing breast, ovarian, and prostate cancers.
|
29540360 |
2018 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The IMPACT study is evaluating PSA screening in men with a known genetic predisposition to PrCa due to BRCA1/2 mutations.
|
29301143 |
2018 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We confirmed that BRCA1/2 mutations confer an up to 4.5-fold and 8.3-fold increased risk of PC, respectively.
|
29242595 |
2018 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Despite having high grade histology and advanced stage at diagnosis, male BRCA1/2 mutation carriers with breast and prostate cancer demonstrated a favorable 5-year survival.
|
29433453 |
2018 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genetic factors contribute to more than 40% of prostate cancer risk, and mutations in BRCA1 and BRCA2 are well-established risk factors.
|
29580149 |
2018 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
"Masculinity theory" was used to report the impact of having both a BRCA1/2 mutation and PCa.
|
28812325 |
2017 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
For example, prostate cancer risk by age 80 years at the 5th and 95th percentiles of the PRS varies from 7% to 26% for carriers of BRCA1 mutations and from 19% to 61% for carriers of BRCA2 mutations, respectively.
|
28448241 |
2017 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline breast cancer 1 gene (BRCA1) and breast cancer 2 gene (BRCA2) mutations are implicated in the highest risk of prostate cancer (PC) predisposition and aggressiveness.
|
28280302 |
2017 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Prostate cancer patients with inherited mutations in BRCA1/2 and ATM are more likely to die of prostate cancer and do so at an earlier age.
|
27989354 |
2017 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PARP inhibitors are gradually being established for therapeutic purposes, with olaparib achieving breakthrough status for prostate cancer patients with BRCA1 and 2 and ATM mutations.
|
28323658 |
2017 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
The use of PARP1 inhibitors is gaining momentum in the treatment of a variety of tumours with BRCA1 involvement including breast, ovarian, pancreatic and prostate cancer.
|
29187880 |
2017 |